Effect of Molecular Hydrogen Administration on Performance and Body Response on Exercise in National-level Fin-swimmers

Sponsor
Palacky University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05799911
Collaborator
(none)
12
1
2
2.7
4.5

Study Details

Study Description

Brief Summary

The aim of this randomized, double-blind, placebo-controlled crossover trial is to evaluate the effect of hydrogen-rich water consumption on performance, recovery, psychological and biochemical outcomes in elite Czech fin-swimmers.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Hydrogen rich water
  • Dietary Supplement: Placebo
N/A

Detailed Description

Twelve Czech national and international-level fin-swimmers participate in this trial. Participants take molecular hydrogen via drinking hydrogen-rich water (HRW) or placebo three days before (1260 ml/day) and during testing day (2520 ml). All participants participate in two testing session and receive HRW and placebo in random order. Each session includes two training units in a 25-m indoor swimming pool and a 24-hour monitored recovery. The first training unit takes place in the morning between 9 and 11 AM and includes three high intensity interval sets. The afternoon training unit includes a continuous 400-m competitive performance. The washout period between testing sessions is 7 days. The variables assessed are as follows: swimming times, heart rate variability, lower limb explosive strength, rating of perceived exertion, subjective perceived muscle soreness, creatine kinase, blood lactate, and protein carbonyls. Statistical analysis is based on analysis of variance for repeated measures with factors: water (HRW and placebo), time, and interaction. Fisher's post-hoc tests is used for pairwise comparisons. The significance level is set at 0.05.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
12 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Masking Description:
Visually indistinguishable packages of hydrogen-rich water and placebo.
Primary Purpose:
Prevention
Official Title:
Effect of Molecular Hydrogen Administration on Performance and Body Response on Repeated Exercise and the Following Recovery in National-level Fin-swimmers: A Randomized, Double-blind, Placebo-controlled Crossover Trial
Actual Study Start Date :
Apr 11, 2023
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Molecular hydrogen

Hydrogen-rich water supplied in 420-ml packages. 3 days before testing day - 3 packages per day, testing day - 6 packages, 15 packages in total.

Dietary Supplement: Hydrogen rich water
Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
Other Names:
  • Aquastamina-R, Nutristamina, Ostrava, Czech Republic
  • Placebo Comparator: Placebo

    Tap water supplied in 420-ml packages. 3 days before testing day - 3 packages per day, testing day - 6 packages, 15 packages in total.

    Dietary Supplement: Placebo
    Tap water with molecular hydrogen concentration 0.0 ppm.
    Other Names:
  • Aquastamina-Placebo, Nutristamina, Ostrava, Czech Republic
  • Outcome Measures

    Primary Outcome Measures

    1. Swimming time for 400 m [Change between values before and after 7 days of crossover.]

      Swimming time is recorded according to swimming and fin-swimming rules. Swimming time is measured by two qualified timekeepers. The longer time is the official time.

    Secondary Outcome Measures

    1. Swimming time for 50 m [Change between values before and after 7 days of crossover.]

      Swimming time is recorded according to swimming and fin-swimming rules. Swimming time is measured by three qualified timekeepers. If two of the three watches record the same time and the third disagrees, the two identical times is the official time. If all three watches disagree, the watch recording the intermediate time is the official time. The 50-m swimming is repeated in 3 sets and 4 rounds, representing 12 measured times.

    2. Heart rate variability [Change between values before and after 7 days of crossover.]

      To determine heart rate variability variables, the ECG signal is measured at a sampling frequency of 1000 Hz using DiANS PF8 (DIMEA Group, Olomouc, Czech Republic). ECG sampling is performed during an orthoclinostatic maneuver (supine-standing-supine) in calm room without any acoustic or visual disturbances. Time domain variables (RMSSD and SDNN) and frequency domain variables (high and low frequency power) are calculated from the ECG. Variables are measured before and after the first training unit, before and after the second training unit, morning and evening of the following day.

    3. Lower limb explosive strength [Change between values before and after 7 days of crossover.]

      The subject performs 3 single maximum effort countermovement jumps with 30 seconds of rest between each jump. The starting position for the jump is an upright posture with the hands placed on the hips. Vertical ground reaction force is measured on 2 parallel force platforms (AMTI OR6-7-1000, Advanced Mechanical Technology, Watertown, USA) with a sampling frequency of 1000 Hz. The jump height is calculated from the measured force-time curve and the average of three jumps is considered for subsequent analysis. The jump height is measured before and after the first training unit, before and after the second training unit, morning and evening of the following day.

    4. Rating of perceived exertion [Change between values before and after 7 days of crossover.]

      The subject is asked to score subjective rating of perceived exertion using the scale developed by Borg. All subjects are familiar with the Borg scale before testing. We use modified scale ranged from 1 (no exertion at all) to 10 (maximum exertion). The rating is scored immediately after each set of 50-m swimming and after 400-m swimming.

    5. Subjective perceived muscle soreness [Change between values before and after 7 days of crossover.]

      Visual analogue scale (VAS) is used to assess lower limb muscle soreness. The VAS is a horizontal 100 mm length line, marked with 0, indicating "no pain" and 100 indicating the "worst imaginable pain". The VAS is assessed before and after the first training unit, before and after the second training unit, morning and evening of the following day.

    6. Creatine kinase [Change between values before and after 7 days of crossover.]

      Creatine kinase is evaluated based on blood samples taken from fingertip. An alcohol wipe is used to clean fingertip and the skin is punctured with lancet. First drop is wiped away and the second drop is used. A Reflotron applicator with a 32 μL disposable pipette tip is used to extract a 32 μL sample of blood and place it on a creatine kinase assay strip (Reflotron CK strips, Roche Diagnostics, Rotkreuz, Switzerland). The blood sample is analyzed using a spectrophotometer (Reflotron Plus, Roche Diagnostics, Rotkreuz, Switzerland) to set plasma creatine kinase concentration.The creatine kinase is evaluated before the first training unit, before the second training unit, morning and evening of the following day.

    7. Blood lactate [Change between values before and after 7 days of crossover.]

      Blood lactate concentration is evaluated based on blood samples taken from fingertip. An alcohol wipe is used to clean fingertip and the skin will be punctured with lancet. First drop is wiped away and the second drop is be used. For lactate sampling the analyzer Lactate Scout+ (EKF Diagnostics, Cardiff, United Kingdom) is used. The blood lactate is evaluated before the first training unit, after each set of 50-m swimming, after swim-up, before and after the second training unit, morning and evening of the following day.

    8. Protein carbonyls [Change between values before and after 7 days of crossover.]

      Protein carbonyls are detected from vein blood sample which is taken from the inside of the elbow by a healthcare specialist. The blood is taken into heparinized vacuum tubes. These is then centrifuged at 1000 g. Subsequently, the blood plasma is separated into cryotubes and frozen at -80 °C until biochemical analysis. Protein carbonyls concentration is measured by ELISA method in accordance with the manufacturer's manual (Protein carbonyl content assay kit, Sigma-Aldrich, Saint Louis, USA). The protein carbonyls is analyzed before the first training unit, before the second training unit, morning and evening of the following day.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years to 30 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Junior or adult Czech fin-swimming representative.

    • Medical eligibility for competitive sport.

    • Good health condition.

    • Signed informed consent.

    Exclusion Criteria:
    • Acute health problems.

    • Not following instructions (free of any supplements three weeks before experiment, free of any medicaments, no caffeine at least 24 hours before experiment).

    • Menstruation in testing session.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Palacky University, Faculty of Physical Culture Olomouc Czechia 77111

    Sponsors and Collaborators

    • Palacky University

    Investigators

    • Principal Investigator: Barbora Sladeckova, MSc, Palacky University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jakub Krejci, Palacky University, Faculty of Physical Culture, Palacky University
    ClinicalTrials.gov Identifier:
    NCT05799911
    Other Study ID Numbers:
    • FTK_2023_11
    First Posted:
    Apr 5, 2023
    Last Update Posted:
    Apr 12, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 12, 2023